<span item_type="fundamental" item_id="1917cc1f9f2d0473a0d3b32b4fdcc4f6" counter_id="ST/US/RGBP" env="prod"></span><span item_type="announcement" item_id="515746300399525633" env="prod"></span><p>Revenue: As of FY2024, the actual value is USD 236.56 K.</p><p>EPS: As of FY2024, the actual value is USD -0.16.</p><p>EBIT: As of FY2024, the actual value is USD -417.22 K.</p><p></p><h3>Operating Expenses</h3><ul><li>Operating expenses decreased to $417,221 in 2024 from $923,509 in 2023, primarily due to reduced consulting and professional fees.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225009968/form10-k.htm"></span></li></ul><h3>Other Income</h3><ul><li>The company reported a net other expense of -$251,034 in 2024, compared to a net other income of $1,843,456 in 2023. This was mainly due to a derivative loss of -$4,091 in 2024 versus a derivative gain of $2,151,755 in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225009968/form10-k.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Net loss for the year ended September 30, 2024 was -$668,255, compared to a net income of $1,156,507 in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225009968/form10-k.htm"></span></li></ul><h3>Working Capital</h3><ul><li>Working capital deficit increased by $58,139 from September 30, 2023 to September 30, 2024, primarily due to an increase in notes payable offset by an increase in accounts receivable.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225009968/form10-k.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities was -$751,536 in 2024, compared to -$173,917 in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225009968/form10-k.htm"></span></li><li>Net cash provided by financing activities was $631,215 in 2024, compared to $243,750 in 2023.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225009968/form10-k.htm"></span></li></ul><h3>Outlook</h3><ul><li>The company has incurred significant operating losses and negative cash flows from operations since inception. As of September 30, 2024, the company had cash of approximately $716 and an accumulated deficit of approximately $20.6 million. The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities to continue operations.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1589150/000164117225009968/form10-k.htm"></span></li></ul>

Regen BioPharma, Inc. | 10-K: FY2024 Revenue: USD 236.56 K